CDR-Life is a biotech startup that specializes in developing innovative immunotherapies for cancer treatment. The company's unique M-gager® technology creates antibody-based T cell engagers that target tumor-specific antigens with high precision. In simpler terms, they are developing a new type of cancer treatment that uses the body's immune system to fight cancer cells.

The company's primary market is the healthcare and pharmaceutical industry, specifically those dealing with cancer treatment. Their clients would primarily be healthcare providers and potentially other pharmaceutical companies interested in their technology.

CDR-Life operates on a business model that involves the discovery, development, and commercialization of their immunotherapies. They generate revenue through the sale of these therapies once they have been approved for use. Additionally, they may also earn income through partnerships with other pharmaceutical companies that wish to use their technology.

Founded in 2017 by a team of experienced drug developers and biotech entrepreneurs, CDR-Life has a strong focus on innovation and the development of superior T cell engaging therapies. The team's broad expertise in antibody discovery, pharmacology, clinical and drug product development positions the company well for breaking new ground in cancer treatment.

Keywords: Biotech, Immunotherapies, Cancer Treatment, M-gager® Technology, Antibody-based T cell Engagers, Healthcare Industry, Pharmaceutical Industry, Drug Development, Innovation, Tumor-specific Antigens.